Last reviewed · How we verify
DWJ1464
DWJ1464, marketed by Daewoong Pharmaceutical Co., Ltd., holds an established position in its therapeutic segment despite the unknown mechanism of action. The drug's key composition patent is set to expire in 2028, which may provide a period of market exclusivity and revenue protection. However, the primary risk lies in the lack of a defined mechanism of action, which could limit its differentiation and attractiveness in the market.
At a glance
| Generic name | DWJ1464 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease (PHASE4)
- An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers (PHASE1)
- Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWJ1464 CI brief — competitive landscape report
- DWJ1464 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI